ArticleInternational journal of nanomedicine2026
Thermosensitive Poloxamer Liposomal Gel for Sustained FTA Delivery Enhances Anti-Breast Cancer Efficacy and Biosafety.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: FTA is a new FT derivative developed by our team by modifying FT with aspirin, and it has been shown to boost anti-breast cancer activity. Methods: To significantly enhance the anti-breast cancer efficacy and biosafety of FTA, this study employed Poloxamer F127 and Poloxamer F68 to construct a composite carrier system, successfully prepared FTA-loaded liposomes (FTA-LN) and their thermosensitive gel formulation (FTA-LN-TSG), with systematic in vitro and in vivo assessments performed. Results: Simultaneously, FTA-LN exhibited an average particle size of 131.03 ± 4.35 nm, polydispersity index (PDI) of 0.265 ± 0.003, zeta potential of -21.46 ± 2.49 mV, and encapsulation efficiency of 94.55 ± 1.10%. FTA-LN followed first-order kinetics, with a cumulative release rate of 68.48% within 4 hours. Conversely, FTA-LN-TSG displayed sustained release characteristics consistent with Higuchi kinetics, reaching a cumulative release of 52.56% at 8 hour. In vitro efficacy evaluation revealed that FTA-LN-TSG exhibited significantly superior inhibitory effects against breast cancer cells compared to FTA (24 h and 48 h inhibition rates: 2.72- and 5.02-fold of FTA; cell migration rate: 37% of FTA). Furthermore, FTA-LN-TSG demonstrated significant differences in inducing apoptosis and cell cycle arrest (Total apoptosis rate of FTA: 25.74, total apoptosis rate of FTA-LN-TSG: 48.84%). Pharmacokinetic results indicated that FTA-LN-TSG exhibited a 3.5-fold prolongation in half-life (t Conclusion: In summary, as a novel drug delivery system, FTA-LN-TSG may represent a promising option for breast cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.